Cato Research, that specializes in drug development support for clients in the pharmaceutical, biotechnology, and medical device industries, has merged with Specialized Medical Services-oncology, a full-service CRO solely dedicated to oncology. Financial terms were not disclosed. By joining forces, CATO and SMS-oncology expand their presence across Europe and North America, deepen their oncology and regulatory expertise, and broaden their suite of services. "CATO and SMS-oncology bring a powerful blend of capabilities focused on supporting small and mid-sized biotech and pharmaceutical companies with their innovative research. Our companies share strong cultural values, anchored by a commitment to high quality and personalized customer service. Together, we're focused on growing and enhancing our services to build an industry-leading company specializing in complex therapeutic areas, including oncology, cell and gene therapy, and rare treatments," Mark Goldberg, CATO Executive Chairman.